Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study

To assess the safety and efficacy of different doses of RTH258 applied as single intravitreal administration compared with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (AMD). Six-month, phase 1/2, prospective, multicenter, double-masked, randomized, ascending sing...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 123; no. 5; p. 1080
Main Authors:	Holz, Frank G, Dugel, Pravin U, Weissgerber, Georges, Hamilton, Robin, Silva, Rufino, Bandello, Francesco, Larsen, Michael, Weichselberger, Andreas, Wenzel, Andreas, Schmidt, Anne, Escher, Dominik, Sararols, Laura, Souied, Eric
Format:	Journal Article
Language:	English
Published:	United States 01.05.2016
Subjects:	Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Double-Blind Method Female Fluorescein Angiography Humans Immunoglobulin Fragments - immunology Intravitreal Injections Male Prospective Studies Ranibizumab - administration & dosage Single-Chain Antibodies - immunology Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity Wet Macular Degeneration - diagnosis Wet Macular Degeneration - physiopathology Wet Macular Degeneration - therapy
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!